JP6990667B2 - 眼性新血管形成を低減するための組成物および方法 - Google Patents

眼性新血管形成を低減するための組成物および方法 Download PDF

Info

Publication number
JP6990667B2
JP6990667B2 JP2018565844A JP2018565844A JP6990667B2 JP 6990667 B2 JP6990667 B2 JP 6990667B2 JP 2018565844 A JP2018565844 A JP 2018565844A JP 2018565844 A JP2018565844 A JP 2018565844A JP 6990667 B2 JP6990667 B2 JP 6990667B2
Authority
JP
Japan
Prior art keywords
vegf
aav
cases
ranibizumab
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018565844A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521989A (ja
JP2019521989A5 (enExample
Inventor
マーク ブルーメンクランツ，
メヒディ ガスミ，
Original Assignee
アドヴェラム バイオテクノロジーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アドヴェラム バイオテクノロジーズ， インコーポレイテッド filed Critical アドヴェラム バイオテクノロジーズ， インコーポレイテッド
Publication of JP2019521989A publication Critical patent/JP2019521989A/ja
Publication of JP2019521989A5 publication Critical patent/JP2019521989A5/ja
Priority to JP2021197648A priority Critical patent/JP7384447B2/ja
Application granted granted Critical
Publication of JP6990667B2 publication Critical patent/JP6990667B2/ja
Priority to JP2023173614A priority patent/JP7606245B2/ja
Priority to JP2024213242A priority patent/JP2025038012A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Emergency Medicine (AREA)
  • Dispersion Chemistry (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2018565844A 2016-06-16 2017-06-16 眼性新血管形成を低減するための組成物および方法 Active JP6990667B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021197648A JP7384447B2 (ja) 2016-06-16 2021-12-06 眼性新血管形成を低減するための組成物および方法
JP2023173614A JP7606245B2 (ja) 2016-06-16 2023-10-05 眼性新血管形成を低減するための組成物および方法
JP2024213242A JP2025038012A (ja) 2016-06-16 2024-12-06 眼性新血管形成を低減するための組成物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662351231P 2016-06-16 2016-06-16
US62/351,231 2016-06-16
PCT/US2017/038012 WO2017218981A2 (en) 2016-06-16 2017-06-16 Compositions and methods for reducing ocular neovascularization

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021197648A Division JP7384447B2 (ja) 2016-06-16 2021-12-06 眼性新血管形成を低減するための組成物および方法

Publications (3)

Publication Number Publication Date
JP2019521989A JP2019521989A (ja) 2019-08-08
JP2019521989A5 JP2019521989A5 (enExample) 2020-05-28
JP6990667B2 true JP6990667B2 (ja) 2022-02-03

Family

ID=60664289

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018565844A Active JP6990667B2 (ja) 2016-06-16 2017-06-16 眼性新血管形成を低減するための組成物および方法
JP2021197648A Active JP7384447B2 (ja) 2016-06-16 2021-12-06 眼性新血管形成を低減するための組成物および方法
JP2023173614A Active JP7606245B2 (ja) 2016-06-16 2023-10-05 眼性新血管形成を低減するための組成物および方法
JP2024213242A Pending JP2025038012A (ja) 2016-06-16 2024-12-06 眼性新血管形成を低減するための組成物および方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021197648A Active JP7384447B2 (ja) 2016-06-16 2021-12-06 眼性新血管形成を低減するための組成物および方法
JP2023173614A Active JP7606245B2 (ja) 2016-06-16 2023-10-05 眼性新血管形成を低減するための組成物および方法
JP2024213242A Pending JP2025038012A (ja) 2016-06-16 2024-12-06 眼性新血管形成を低減するための組成物および方法

Country Status (19)

Country Link
US (2) US20190100582A1 (enExample)
EP (4) EP4427808B1 (enExample)
JP (4) JP6990667B2 (enExample)
KR (2) KR102622823B1 (enExample)
AU (2) AU2017286680B2 (enExample)
CA (1) CA3027740A1 (enExample)
CY (1) CY1125152T1 (enExample)
DK (1) DK3472317T3 (enExample)
ES (2) ES2916344T3 (enExample)
HR (1) HRP20220612T1 (enExample)
HU (1) HUE059424T2 (enExample)
LT (1) LT3472317T (enExample)
PL (1) PL3472317T3 (enExample)
PT (1) PT3472317T (enExample)
RS (1) RS63282B1 (enExample)
SG (1) SG11201811230RA (enExample)
SI (1) SI3472317T1 (enExample)
SM (1) SMT202200251T1 (enExample)
WO (1) WO2017218981A2 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2822551T3 (es) 2014-03-17 2021-05-04 Adverum Biotechnologies Inc Composiciones y métodos para la expresión génica mejorada en células de los conos
WO2015200905A2 (en) 2014-06-28 2015-12-30 Oligasis, Llc Dual pdgf/vegf antagonists
FI3265178T3 (fi) 2015-03-02 2026-08-03 Adverum Biotechnologies Inc Koostumuksia ja menetelmiä polynukleotidien viemiseksi intravitreaalisesti retinaalisiin tappisoluihin
IL290457B2 (en) 2015-12-30 2025-02-01 Kodiak Sciences Inc Antibodies and their conjugates
PL3472317T3 (pl) * 2016-06-16 2022-08-08 Adverum Biotechnologies, Inc. Kompozycje i sposoby zmniejszania neowaskularyzacji oka
AU2017345470B2 (en) 2016-10-19 2023-08-03 Adverum Biotechnologies, Inc. Modified AAV capsids and uses thereof
KR102616820B1 (ko) 2017-03-17 2023-12-21 애드베룸 바이오테크놀로지스, 인코포레이티드 향상된 유전자 발현을 위한 조성물 및 방법
CA3086045A1 (en) 2017-12-19 2019-06-27 Akouos, Inc. Aav-mediated delivery of therapeutic antibodies to the inner ear
CA3092588A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
CN118001307A (zh) * 2018-03-30 2024-05-10 藤堂具纪 肿胀发生抑制型溶瘤病毒
US20220195462A1 (en) * 2019-04-24 2022-06-23 Regenxbio Inc. Fully-human post-translationally modified antibody therapeutics
PE20240329A1 (es) 2019-06-05 2024-02-27 Regeneron Pharma Dispositivos y metodos para administracion de dosis de precision
WO2021046245A1 (en) * 2019-09-04 2021-03-11 University Of Massachusetts Adeno-associated virus vector platform for delivery of kh902 (conbercept) and uses thereof
JP7893739B2 (ja) * 2019-09-11 2026-07-23 アドヴェラム バイオテクノロジーズ， インコーポレイテッド アフリベルセプトをコードするａａｖ２バリアントを使用する眼内血管新生疾患を処置する方法
WO2021071835A1 (en) * 2019-10-07 2021-04-15 Regenxbio Inc. Adeno-associated virus vector pharmaceutical composition and methods
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
CN115335529B (zh) * 2019-11-26 2026-07-03 马萨诸塞大学 用于递送kh902(康柏西普)的重组腺相关病毒及其用途
US20230149428A1 (en) * 2020-02-14 2023-05-18 Asklepios Biopharmaceutical, Inc. Method of treating gene therapy associated toxicity with antibiotics
IL303317A (en) 2020-12-01 2023-07-01 Akouos Inc ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA
JP2022108271A (ja) * 2021-01-12 2022-07-25 Ｊｃｒファーマ株式会社 リガンドと生理活性を有する蛋白質の融合蛋白質をコードする遺伝子が組み込まれた核酸分子
US12649031B2 (en) 2021-09-08 2026-06-09 Regeneron Pharmaceuticals, Inc. Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN115869425B (zh) * 2022-12-12 2024-08-20 北京生物制品研究所有限责任公司 一种aav眼用注射液及其制备方法和应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014518614A (ja) 2011-04-22 2014-08-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 変異体キャプシドを有するアデノ関連ウイルスビリオンおよびその使用方法
JP2015523060A (ja) 2012-05-15 2015-08-13 アバランチ オーストラリア プロプライエタリー リミテッド Ａａｖｓｆｌｔ−１を用いたａｍｄの処置

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3734262B2 (ja) 1993-03-25 2006-01-11 メルク エンド カンパニー インコーポレーテッド 血管内皮細胞増殖因子阻害剤
EP2346532B1 (en) * 2008-10-07 2020-10-07 Bracco Suisse SA Targeting construct comprising anti-polymer antibody and microvesicles binding to the same
US8663624B2 (en) * 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
ES2822551T3 (es) * 2014-03-17 2021-05-04 Adverum Biotechnologies Inc Composiciones y métodos para la expresión génica mejorada en células de los conos
PL3472317T3 (pl) * 2016-06-16 2022-08-08 Adverum Biotechnologies, Inc. Kompozycje i sposoby zmniejszania neowaskularyzacji oka
WO2018134168A1 (en) * 2017-01-17 2018-07-26 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of expressing a polynucleotide of interest in the cone photoreceptors
JP2021197648A (ja) * 2020-06-16 2021-12-27 ソニーセミコンダクタソリューションズ株式会社 固体撮像素子、撮像装置、および、固体撮像素子の制御方法
JP7743369B2 (ja) * 2022-05-26 2025-09-24 日本キヤリア株式会社 電力変換装置

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014518614A (ja) 2011-04-22 2014-08-07 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 変異体キャプシドを有するアデノ関連ウイルスビリオンおよびその使用方法
JP2015523060A (ja) 2012-05-15 2015-08-13 アバランチ オーストラリア プロプライエタリー リミテッド Ａａｖｓｆｌｔ−１を用いたａｍｄの処置

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Journal of Ocular Pharmacology and Therapeutics，2015年，Vol.31,No.5,pp.269-276
Science Translational Medicine，2013年，Vol.5,No.189,pp.189ra76

Also Published As

Publication number Publication date
SMT202200251T1 (it) 2022-07-21
JP2019521989A (ja) 2019-08-08
JP7384447B2 (ja) 2023-11-21
SI3472317T1 (sl) 2022-08-31
AU2023202277A1 (en) 2023-05-11
EP4083203A1 (en) 2022-11-02
HUE059424T2 (hu) 2022-11-28
JP2022028928A (ja) 2022-02-16
EP3472317A4 (en) 2020-02-26
DK3472317T3 (da) 2022-05-23
EP4427808B1 (en) 2026-05-20
US20230322911A1 (en) 2023-10-12
CA3027740A1 (en) 2017-12-21
EP4083203C0 (en) 2024-08-07
AU2023202277B2 (en) 2026-05-07
EP4427808A3 (en) 2024-10-30
WO2017218981A3 (en) 2018-02-15
ES2916344T3 (es) 2022-06-30
KR20190038536A (ko) 2019-04-08
RS63282B1 (sr) 2022-06-30
PT3472317T (pt) 2022-06-27
EP4083203B1 (en) 2024-08-07
WO2017218981A2 (en) 2017-12-21
EP3472317A2 (en) 2019-04-24
KR20220162881A (ko) 2022-12-08
SG11201811230RA (en) 2019-01-30
JP7606245B2 (ja) 2024-12-25
US20190100582A1 (en) 2019-04-04
JP2025038012A (ja) 2025-03-18
AU2017286680A1 (en) 2019-01-31
EP3472317B1 (en) 2022-03-16
JP2023171953A (ja) 2023-12-05
EP4674483A2 (en) 2026-01-07
LT3472317T (lt) 2022-06-27
PL3472317T3 (pl) 2022-08-08
ES2987337T3 (es) 2024-11-14
CY1125152T1 (el) 2024-12-13
HRP20220612T1 (hr) 2022-07-22
EP4427808A2 (en) 2024-09-11
AU2017286680B2 (en) 2023-01-19
KR102622823B1 (ko) 2024-01-10
EP4674483A3 (en) 2026-03-25

Similar Documents

Publication Publication Date Title
JP7384447B2 (ja) 眼性新血管形成を低減するための組成物および方法
JP6814822B2 (ja) アフリベルセプトを含むａａｖ２バリアントを使用したａｍｄの処置
JP7597380B2 (ja) 対側眼へのａａｖ遺伝子治療の逐次的硝子体内投与
JP2023544803A (ja) Ｃｌｎ２疾患の眼症状に対する遺伝子療法
HK40082757B (en) Compositions and methods for reducing ocular neovascularization
HK40115902A (en) Compositions and methods for reducing ocular neovascularization
HK40082757A (en) Compositions and methods for reducing ocular neovascularization
HK40008120A (en) Compositions and methods for reducing ocular neovascularization
HK40008120B (en) Compositions and methods for reducing ocular neovascularization
HK40049262B (en) Treatment of amd using aav2 variant with aflibercept
HK40007499A (en) Treatment of amd using aav2 variant with aflibercept

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200415

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200415

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210716

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20211105

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20211206

R150 Certificate of patent or registration of utility model

Ref document number: 6990667

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02